Astrazeneca (AZN) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended December 2024, Astrazeneca (AZN) reported revenue of $14.89 billion, up 23.8% over the same period last year. EPS came in at $1.05, compared to $0.73 in the year-ago quarter.The reported revenue represents a surprise of +4.26% over the Zacks Consensus Estimate of $14.28 billion. With the consensus EPS estimate being $1.07, the EPS surprise was -1.87%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Here is how Astrazeneca performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: BioPharmaceuticals- R&I- Symbicort- U.S. $299 million versus the two-analyst average estimate of $235.06 million. Oncology- Truqap- Established RoW: $4 million versus $3.50 million estimated by two analysts on average. Oncology- Tagrisso- U.S. $767 million versus $709.65 million estimated by two analysts on average. BioPharmaceuticals- R&I- Fasenra- U.S. $299 million versus $272.75 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +8.7% change. Collaboration Revenue- Total: $815 million versus the four-analyst average estimate of $419.12 million. Alliance Revenue- Total: $714 million versus $615.99 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +68.4% change. BioPharmaceuticals- CVRM- Seloken/Toprol-XL- World: $140 million compared to the $146.96 million average estimate based on three analysts. The reported number represents a change of -2.8% year over year. Oncology- Tagrisso- World: $1.70 billion versus $1.68 billion estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +20% change. BioPharmaceuticals- V&I- Synagis- World: $101 million compared to the $102.19 million average estimate based on three analysts. BioPharmaceuticals- R&I- Fasenra- World: $471 million versus the three-analyst average estimate of $437.04 million. BioPharmaceuticals- CVRM- Brilinta- World: $341 million versus the three-analyst average estimate of $310.89 million. The reported number represents a year-over-year change of +3.7%. BioPharmaceuticals- CVRM- Farxiga- World: $1.93 billion compared to the $1.96 billion average estimate based on three analysts. The reported number represents a change of +20.4% year over year. View all Key Company Metrics for Astrazeneca here>>>Shares of Astrazeneca have returned +6.5% over the past month versus the Zacks S&P 500 composite's +2.1% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.7 Best Stocks for the Next 30 DaysJust released: Experts distill 7 elite stocks from the current list of 220 Zacks Rank #1 Strong Buys. They deem these tickers "Most Likely for Early Price Pops."Since 1988, the full list has beaten the market more than 2X over with an average gain of +24.3% per year. So be sure to give these hand picked 7 your immediate attention. See them now >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report AstraZeneca PLC (AZN): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks